Opportunity Information: Apply for PAR 23 148
The Pulmonary Outcomes and Sequelae after Treatment-TB (POST-TB) (R01 Clinical Trial Optional) funding opportunity (PAR-23-148) is a National Institutes of Health (NIH) discretionary grant program designed to build stronger evidence about what happens to people after they complete tuberculosis (TB) treatment, with a particular focus on longer-term heart and lung problems. The core idea is that finishing TB therapy does not always mean a full return to health, and many individuals experience ongoing or delayed cardiopulmonary complications and reduced quality of life. This FOA supports epidemiological and observational research that can better measure, describe, and explain those post-treatment outcomes so the field can move toward clearer definitions of post-TB morbidity, improved follow-up care, and more targeted interventions.
A central feature of the announcement is its emphasis on leveraging existing cohorts rather than starting entirely new ones. Applicants are expected to propose additional testing, enhanced follow-up, and new data collection within cohorts of adult and/or pediatric participants who have had TB disease. In practical terms, that means adding deeper phenotyping, strengthening longitudinal outcome tracking, or introducing new clinical assessments in groups that are already being followed. The research focus is explicitly on long-term sequelae after TB treatment, especially cardiopulmonary outcomes, and the FOA highlights the importance of understanding these adverse outcomes in people with and without HIV infection. This inclusion matters because HIV can change TB disease severity, recovery trajectories, and the risk profile for chronic lung and cardiovascular problems, so studies that can compare or stratify by HIV status can help clarify mechanisms and identify groups at higher risk.
Because the mechanism is an R01, the program is geared toward substantial, hypothesis-driven projects with enough scope to produce rigorous and generalizable findings. At the same time, the FOA frames the work as epidemiological and observational, meaning the primary intent is not necessarily to test a new therapeutic intervention, but to characterize disease burden, patterns of morbidity, risk factors, and trajectories over time. The label "Clinical Trial Optional" signals that a clinical trial is not required for this opportunity, and applicants can remain fully within observational designs; however, if a project includes elements that meet the definition of a clinical trial, it is not automatically disqualified, provided it aligns with the FOA and NIH policies.
Eligible applicants are broad and include many types of U.S. organizations and governments: state, county, city/township, and special district governments; independent school districts; public and state-controlled institutions of higher education; private institutions of higher education; Native American tribal governments that are federally recognized; public housing authorities/Indian housing authorities; and tribal organizations that are not federally recognized tribal governments. The FOA also allows nonprofit organizations both with and without 501(c)(3) status, for-profit organizations (other than small businesses), and small businesses, along with other eligible entities. In addition to these standard NIH eligibility categories, the announcement specifically calls out a range of other eligible applicants that NIH often encourages to broaden participation and strengthen community relevance, including Alaska Native and Native Hawaiian Serving Institutions, Asian American Native American Pacific Islander Serving Institutions (AANAPISIs), Hispanic-serving Institutions, Historically Black Colleges and Universities (HBCUs), Tribally Controlled Colleges and Universities (TCCUs), faith-based or community-based organizations, eligible federal agencies, U.S. territories or possessions, regional organizations, and non-U.S. (foreign) organizations. The inclusion of foreign organizations is particularly relevant for TB research because a large share of TB burden occurs outside the United States, and established international cohorts can be critical for studying post-TB outcomes at scale and across diverse settings.
From an administrative standpoint, the opportunity is listed under CFDA (Assistance Listing) 93.855 and is categorized under the health funding activity area. The Funding Opportunity Number is PAR-23-148, with the opportunity created on March 30, 2023. The original closing date shown is May 7, 2026. While the public summary does not provide an award ceiling or expected number of awards, the intent is clearly to support multiple investigator-initiated projects that can add meaningful new information to existing TB cohorts and help the field understand the longer-term cardiopulmonary burden that persists after microbiologic cure.
Overall, this FOA is aimed at strengthening the evidence base around post-TB cardiopulmonary health by encouraging investigators to take advantage of existing TB cohorts, add targeted assessments, and generate high-quality observational data. The long-term payoff is better identification of who is at risk for chronic complications after TB treatment, clearer clinical characterization of post-TB sequelae, and a stronger foundation for future prevention strategies, clinical guidelines, and intervention studies.Apply for PAR 23 148
- The National Institutes of Health in the health sector is offering a public funding opportunity titled "Pulmonary Outcomes and Sequelae after Treatment-TB (POST-TB) (R01 Clinical Trial Optional)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.855.
- This funding opportunity was created on 2023-03-30.
- Applicants must submit their applications by 2026-05-07. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For-profit organizations other than small businesses, Small businesses, Others.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Frequently Asked Questions (FAQs)
What is the POST-TB funding opportunity (PAR-23-148) about?
PAR-23-148 (Pulmonary Outcomes and Sequelae after Treatment-TB, or POST-TB) is an NIH discretionary grant opportunity that supports research on what happens to people after they complete tuberculosis (TB) treatment. The emphasis is on longer-term outcomes, especially heart and lung (cardiopulmonary) complications and quality-of-life impacts that can persist or appear after treatment ends.
Why does NIH focus on outcomes after TB treatment is completed?
The program is built on the idea that completing TB therapy does not always mean a full return to health. Many people experience ongoing or delayed cardiopulmonary problems and reduced quality of life even after microbiologic cure. This opportunity supports work that can better measure, describe, and explain those outcomes so the field can improve follow-up care and move toward clearer definitions of post-TB morbidity.
What kinds of research does this FOA support?
The FOA supports epidemiological and observational research intended to characterize post-treatment TB outcomes over time. Projects are expected to generate evidence on disease burden, patterns of morbidity, risk factors, and trajectories, particularly for cardiopulmonary sequelae after TB treatment.
Is this funding opportunity limited to lung outcomes only?
No. While pulmonary outcomes are central, the FOA explicitly highlights longer-term cardiopulmonary outcomes, which includes both lung and heart-related complications after TB treatment.
Does the FOA require starting a brand-new study cohort?
No. A central feature of this announcement is an emphasis on leveraging existing cohorts rather than starting entirely new ones. Applicants are expected to propose additional testing, enhanced follow-up, and new data collection within cohorts of adult and/or pediatric participants who have had TB disease.
What does it mean to "leverage existing cohorts" in practical terms?
Based on the FOA summary, it means building on groups that are already being followed by adding components such as deeper phenotyping, strengthened longitudinal outcome tracking, and/or introducing new clinical assessments. The intent is to extend and enrich ongoing cohort work to better capture post-TB sequelae.
Are both adults and children eligible to be studied under this FOA?
Yes. The FOA notes that applicants may propose work within existing cohorts of adult and/or pediatric participants who have had TB disease.
What is the main scientific focus of the opportunity?
The research focus is explicitly on long-term sequelae after TB treatment, especially cardiopulmonary outcomes. The FOA is geared toward improving measurement and understanding of these post-treatment outcomes so the field can move toward clearer clinical characterization and better care pathways.
Does the FOA address people with HIV as well as those without HIV?
Yes. The FOA highlights the importance of understanding post-treatment adverse outcomes in people with and without HIV infection. HIV status is considered important because it can affect TB severity, recovery trajectories, and risk for chronic lung and cardiovascular problems, and stratified or comparative analyses can help clarify mechanisms and identify higher-risk groups.
What grant mechanism is used for this opportunity?
This opportunity uses the NIH R01 mechanism, which is intended for substantial, hypothesis-driven projects with enough scope to produce rigorous and generalizable findings.
Does the applicant need to propose a clinical trial?
No. The FOA is labeled "Clinical Trial Optional," which means a clinical trial is not required. Projects can be fully observational in design.
If a project includes a clinical trial component, is it allowed?
Potentially, yes. The "Clinical Trial Optional" designation indicates that if a proposed project includes elements that meet the NIH definition of a clinical trial, it is not automatically disqualified, as long as the project aligns with the FOA and NIH policies.
Who can apply for PAR-23-148?
Eligible applicants are broad and include many U.S. organizations and governments, such as state, county, city/township, and special district governments; independent school districts; public and state-controlled institutions of higher education; private institutions of higher education; federally recognized Native American tribal governments; public housing authorities/Indian housing authorities; and tribal organizations that are not federally recognized tribal governments.
Are nonprofits eligible to apply?
Yes. The FOA allows nonprofit organizations both with and without 501(c)(3) status to apply.
Are for-profit organizations eligible to apply?
Yes. For-profit organizations (other than small businesses) are listed as eligible applicants, and small businesses are also included among eligible entities.
Are small businesses eligible to apply?
Yes. Small businesses are included among eligible applicants in the provided summary.
Can faith-based or community-based organizations apply?
Yes. The opportunity specifically calls out faith-based or community-based organizations among other eligible applicant types.
Are minority-serving institutions and similar organizations eligible?
Yes. The FOA specifically includes organizations such as Alaska Native and Native Hawaiian Serving Institutions, AANAPISIs, Hispanic-serving Institutions, HBCUs, and TCCUs among eligible applicants.
Can federal agencies apply?
Yes. The summary lists eligible federal agencies among eligible applicants.
Are U.S. territories or possessions eligible?
Yes. U.S. territories or possessions are included in the listed eligible applicants.
Are foreign (non-U.S.) organizations eligible to apply?
Yes. The FOA includes non-U.S. (foreign) organizations as eligible applicants. This is particularly relevant for TB research because a large share of TB burden occurs outside the United States, and established international cohorts can support large-scale and diverse post-TB outcome studies.
What is the Assistance Listing (CFDA) number for this opportunity?
The Assistance Listing (CFDA) number provided is 93.855.
What funding activity area does this opportunity fall under?
It is categorized under the health funding activity area.
What is the Funding Opportunity Number?
The Funding Opportunity Number is PAR-23-148.
When was this opportunity created?
The opportunity was created on March 30, 2023.
What is the closing date shown for this opportunity?
The original closing date shown is May 7, 2026.
Does the summary provide an award ceiling or expected number of awards?
No. Based on the provided information, the public summary does not specify an award ceiling or the expected number of awards.
What is the overall goal or intended impact of this FOA?
The FOA aims to strengthen the evidence base around post-TB cardiopulmonary health by encouraging investigators to use existing TB cohorts, add targeted assessments, and generate high-quality observational data. The intended long-term payoff is better identification of who is at risk for chronic complications after TB treatment, clearer clinical characterization of post-TB sequelae, and a stronger foundation for future prevention strategies, clinical guidelines, and intervention studies.
Browse more opportunities from the same category: Health
Next opportunity: F23AS00330 White-nose Syndrome Grants to States and Tribes - 2023
Previous opportunity: Cooperative Agreement for CESU-affiliated University with Rocky Mountain Cooperative Ecosystem Studies Unit
Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for PAR 23 148
Applicants also applied for:
Applicants who have applied for this opportunity (PAR 23 148) also looked into and applied for these:
| Funding Opportunity |
|---|
| Developing Measures to Advance Access and Quality in Global Mental Health Services (R34 Clinical Trial Not Allowed) Apply for RFA MH 23 300 Funding Number: RFA MH 23 300 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Implementing and Evaluating New Models for Delivering Comprehensive, Coordinated, Person-Centered Care to People with Long COVID (U18) Apply for RFA HS 23 012 Funding Number: RFA HS 23 012 Agency: Agency for Health Care Research and Quality Category: Health Funding Amount: Case Dependent |
| Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) Collaborative Research Centers (CRCs) (U54 Clinical Trial Optional) Apply for RFA NS 24 022 Funding Number: RFA NS 24 022 Agency: National Institutes of Health Category: Health Funding Amount: $1,200,000 |
| Limited Competition: NEI - DOD Vision Research Collaborative (R01 Clinical Trial Optional) Apply for PAR 23 141 Funding Number: PAR 23 141 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| NIDCR Prospective Observational or Biomarker Validation Study Cooperative Agreement (U01 Clinical Trial Not Allowed) Apply for PAR 23 162 Funding Number: PAR 23 162 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Core Centers for Clinical Research (CCCR) (P30 Clinical Trial Not Allowed) Apply for RFA AR 24 003 Funding Number: RFA AR 24 003 Agency: National Institutes of Health Category: Health Funding Amount: $500,000 |
| Developing Measures to Advance Quality in Mental Health Care Services (R01 Clinical Trial Not Allowed) Apply for RFA MH 23 265 Funding Number: RFA MH 23 265 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Fundamental Research to Understand the Mechanisms of Neurotropic Virus-mediated Disease (R01 Clinical Trial Not Allowed) Apply for RFA AI 23 028 Funding Number: RFA AI 23 028 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Understanding Persistent Oral Human Papillomavirus and Human Immunodeficiency Virus Co-infection and Its Role with Oropharyngeal Cancer Induction (R21 Clinical Trial Not Allowed) Apply for RFA DE 24 002 Funding Number: RFA DE 24 002 Agency: National Institutes of Health Category: Health Funding Amount: $275,000 |
| Development and Application of PET and SPECT Imaging Ligands as Biomarkers for Drug Discovery and for Pathophysiological Studies of CNS Disorders (R01 Clinical Trial Not Allowed) Apply for PAR 23 165 Funding Number: PAR 23 165 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Development and Application of PET and SPECT Imaging Ligands as Biomarkers for Drug Discovery and for Pathophysiological Studies of CNS Disorders (R01 Clinical Trial Optional) Apply for PAR 23 164 Funding Number: PAR 23 164 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Development and Validation of Models for Alzheimers Disease-Related Dementias (ADRD) (R61/R33 - Clinical Trial Not Allowed) Apply for PAR 23 154 Funding Number: PAR 23 154 Agency: National Institutes of Health Category: Health Funding Amount: $360,000 |
| Institutional Training Programs to Advance Translational Research on Alzheimer's Disease (AD) and AD-Related Dementias (ADRD) (T32 Clinical Trial Not Allowed) Apply for PAR 23 163 Funding Number: PAR 23 163 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Centers of Excellence in Genomic Science (RM1 Clinical Trial Optional) Apply for PAR 23 098 Funding Number: PAR 23 098 Agency: National Institutes of Health Category: Health Funding Amount: $1,500,000 |
| Individually Measured Phenotypes to Advance Computational Translation in Mental Health (IMPACT-MH): Data Coordinating Center (U24 Clinical Trial Not Allowed) Apply for RFA MH 23 106 Funding Number: RFA MH 23 106 Agency: National Institutes of Health Category: Health Funding Amount: $1,000,000 |
| Individually Measured Phenotypes to Advance Computational Translation in Mental Health (IMPACT-MH) (U01 Clinical Trial Optional) Apply for RFA MH 23 105 Funding Number: RFA MH 23 105 Agency: National Institutes of Health Category: Health Funding Amount: $2,500,000 |
| International Research in Infectious Diseases (R01 Clinical Trial Not Allowed) Apply for RFA AI 23 023 Funding Number: RFA AI 23 023 Agency: National Institutes of Health Category: Health Funding Amount: $125,000 |
| Industrialization and Translation of Extracellular Vesicles for use in Regenerative Medicine (UT1/UT2) Clinical Trial Not Allowed Apply for PAR 23 268 Funding Number: PAR 23 268 Agency: National Institutes of Health Category: Health Funding Amount: $295,924 |
| Industrialization and Translation of Extracellular Vesicles for use in Regenerative Medicine (U43/U44 Clinical Trials Not Allowed) Apply for PAR 23 267 Funding Number: PAR 23 267 Agency: National Institutes of Health Category: Health Funding Amount: $295,924 |
| Assay Development and Screening for Discovery of Validated Chemical Hits for Brain Disorders (R01 Clinical Trial Not Allowed) Apply for PAR 23 168 Funding Number: PAR 23 168 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Inside Our Applicants Portal
Access Applicants Portal
- Grants Repository - Access current and historic funding opportunities with ease. Thousands of funding opportunities are published every week. We can help you sort through the database and find the eligible ones to apply for.
- Applicant Video Guides - The grant application process can be challenging to follow. We can help you with intuitive video guides to speed up the process and eliminate errors in submissions.
- Grant Proposal Wizard - We have developed a network of private funding organizations and investors across the United States. We can reach out and submit your proposal to these contacts to maximize your chances of getting the funding you need.
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Learn More
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "PAR 23 148", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.